TelyRx Holdings Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-5.43	-13.48	-4.39
Depreciation & Amortization	0.33	0.09	0.03
Other Amortization	0.46	0.19	-
Loss (Gain) From Sale of Assets	0	-	-
Stock-Based Compensation	-	3.2	-
Other Operating Activities	0.6	9.59	3.71
Change in Accounts Receivable	-0.08	-0.38	-0
Change in Inventory	-0.89	-0.4	-0.06
Change in Accounts Payable	1.68	0.83	-0.23
Change in Other Net Operating Assets	2.56	0.16	-0.01
Operating Cash Flow	-0.77	-2.86	-2.47
Capital Expenditures	-0.59	-0.21	-0.04
Sale (Purchase) of Intangibles	-0.86	-0.53	-0.32
Investment in Securities	-	-0.44	-
Other Investing Activities	-	-0.25	-
Investing Cash Flow	-1.44	-1.43	-0.36
Long-Term Debt Issued	2	0.86	0.06
Long-Term Debt Repaid	-0.11	-0.18	-
Net Debt Issued (Repaid)	1.89	0.68	0.06
Issuance of Common Stock	-	6.55	0.29
Repurchase of Common Stock	-0	-	-
Other Financing Activities	-	-0.06	-0.09
Financing Cash Flow	1.89	7.17	0.26
Net Cash Flow	-0.33	2.88	-2.57
Free Cash Flow	-1.36	-3.07	-2.51
Free Cash Flow Margin	-3.16%	-32.17%	-9277.78%
Free Cash Flow Per Share	-0.13	-0.40	-
Cash Interest Paid	0.11	0.05	-
Levered Free Cash Flow	-0.14	3.09	-
Unlevered Free Cash Flow	0.27	3.67	-
Change in Working Capital	3.27	0.21	-0.3

Source: S&P Global Market Intelligence. Standard template. Financial Sources.